Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib
- 8 November 2011
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 104 (8) , 901-906
Abstract
Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR with greater potency or possess broader kinase inhibition profiles including VEGFR. To circumvent secondary mutations in KIT/PDGFR, inhibition of the downstream signaling in PI3K/Akt/mTOR pathway and enhanced degradation of KIT/PDGFR are also under investigation. J. Surg. Oncol. 2011; 104:901–906.Keywords
This publication has 43 references indexed in Scilit:
- Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)Oncology Reports, 2009
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJournal of Clinical Oncology, 2008
- Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumoursHistopathology, 2008
- Heterogeneity of kinase inhibitor resistance mechanisms in GISTThe Journal of Pathology, 2008
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal of Cancer, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998